Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
"It's not about what they tell you, it's about what they don't."
~ Bob Fiddaman, Author, Blogger, Researcher, Recipient of two Human Rights awards
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Knoppert-Paroxetine Toxicity in a Newborn After in Utero Exposure-TDM-2006
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
The first documentary, 'The Secrets of Seroxat' was aired in 2002 and saw 65,000 people ring the BBC helpline and they received over 1,500 emails. This prompted Shelley to make a follow-up programme called 'Emails from the Edge', which was broadcast on BBC TV on the 11th May 2003. 'Taken on Trust', her third investigation in to Seroxat, shook the foundations of the MHRA to the core as she exposed how they had failed the British public regarding thier ignorance and incompetence. Her fourth and final installment [thus far] of the whole Seroxat scandal was called 'Secrets of the Drug Trials', she showed how GlaxoSmithKline (GSK) attempted to show that Seroxat worked for depressed children despite failed clinical trials. This was aired in 2007.
On November the 1st, 2007, Shelley shed further light on her investigations into Seroxat when she was interviewed at Coventry University as part of the 'Coventry Conversations' series. The interview is available for download and is over an hour in length.
The interview with Shelley is a pretty amazing insight into how GlaxoSmithKline saw her as a major nuisance as she kept chipping away at them, digging for answers.
Shelley Jofre is a terrific reporter, a constant thorn in the side of GlaxoSmithKline and the MHRA. If there were any justice in this world then Shelley should recieve all the accolades. She put the dangers of Seroxat on the map here in the UK, she exposed the clandestine goings-on at the world's second largest pharmaceutical company and the body that regulate them, the MHRA.
A key point in these four documentaries was when she asked Head of European Psychiatry , for GlaxoSmithKline, Alistair Benbow, if Seroxat could be safe in children. His reply still baffles me to this day, he answered, "Absolutely. It could be. We haven't got a license in children yet..."
Quite why Benbow would suggest that Seroxat could be safe in children and would suggest that they hadn't got a license in children 'yet', is quite revealing. His company, GlaxoSmithKline, had documents from 1998 that showed that medication for adolescent depression failed to demonstrate any benefit for paroxetine over placebo in adolescents and demonstrated a worrying profile of adverse events for paroxetine.
I think it is fair to assume that Benbow was either lying or he didn't know that his company knew Seroxat was not beneficial to children, in fact it was quite the reverse. If the latter is true then Benbow as Head of European Psychiatry , at GlaxoSmithKline should ask himself why his employers never told him.
I got myself in to hot water when I created a video with comments from Benbow and juxtaposed them with comments from patients and the mainstream media. Apparently I had caused Benbow distress. Surely, as a consumer of their product, Seroxat, I had every right to question Benbow? Glaxo's lawyers were not happy with a comment I made regarding Benbow, I likened him to a Nazi dictator. In hindsight that was wrong, however, the question of whether Benbow lied on national TV has still not been answered.
Here is the interview with Shelley. It was conducted by John Mair and recorded in front of an audience at Coventry University.
It is an audio recording and not a video.
Right click and 'save as'
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
My postman rang my bell today, he had a package for me. There I was thinking my stalker had decided to send me an early Christmas present... in fact it was better than that, so much better.
I'm about to start reading 'Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial' , a book written by Alison Bass.
From the Inside Flap
As the mental health reporter for the Boston Globe, Alison Bass's front-page reporting on conflicts of interest in medical research stunned readers, and her series on sexual misconduct among psychiatrists earned her a Pulitzer Prize nomination. Now she turns her investigative skills to a landmark case that exposed increased suicide rates among adolescents taking popular antidepressants such as Paxil, Prozac, and Zoloft.
In Side Effects we meet a courageous Ivy League university employee who risked her job to expose suspicious practices at her lab, a feisty assistant attorney general who spearheaded an unprecedented lawsuit against a pharmaceutical giant, plus the medical researchers who were being paid by the drug companies whose products they were testing. And Bass introduces us to the vulnerable children and adults placed at risk because of greed, corruption, and negligence.
Though pediatric prescriptions of Paxil—at the time one of the world's bestselling antidepressants—were soaring, there was no hard proof that the drug performed any better than sugar pills in children and adolescents. Bass reveals how data from drug trials and the suicide risk the drug posed were withheld, allowing GlaxoSmithKline, the maker of Paxil, to mislead physicians and consumers about the safety and efficacy of the drug.
When the New York State attorney general's office brought its lawsuit against GlaxoSmithKline for consumer fraud, it launched a tidal wave of protest. As a result of this case, drug companies agreed to publish negative results from their research studies. A congressional investigation into industry practices finally prompted the FDA to mandate strict warnings for all antidepressants.
In the tradition of A Civil Action, Side Effects goes behind the scenes of the headline-making case that forced the government to start protecting its citizens. It lays bare the unhealthy state of our country's pharmaceutical industry.
****
Alison has placed some documents on her blog. She writes:
The first document here is from the final GlaxoSmithKline report of study 329 (publicly available on its website), which shows that a 14-year-old boy who was in the Paxil arm of the study lost control, punching pictures, breaking glass and injuring himself in November 1994. He was hospitalized and seen as suicidal by the psychiatrists treating him. Yet this patient , known as #65 in the study, was not labeled as suicidal when the study was published in the July 2001 issue of the Journal of the American Academy of Child and Adolescent Psychiatry. (The following year, Paxil became the most widely prescribed antidepressant in the U.S.).
The second document here is a memo to Brown University's Institutional Review Board from Martin Keller, chief of psychiatry at Brown and principal investigator of study 329. In the memo, Keller reports that a teenager in the Paxil study was hospitalized in September 1995 due to becoming combative and suicidal. Yet in the memo, Keller says he has labeled this patient (#106) as noncompliant instead of suicidal as a result of taking Paxil. Likewise in the published 2001 study, this teenager is labeled noncomplaint and not included in the list of adolescents withdrawn from the study as the result of adverse side effects.
The third and perhaps most mysterious document is a memo from Keller to the IRBs at Brown and two of its affiliated hospitals, Butler and Bradley. In this January 30, 1995 memo, Keller reports that a teenage girl, patient #70 in study 329, ingested 82 Tylenol pills on January 19 and was hospitalized at St. Ann's Hospital. She was discontinued from the study at the end of January and coded as noncompliant according to another memo from Keller to Brown's IRB here. Yet according to the GlaxoSmithKline's final report, patient #70 in the same study was a 12-year-old boy enrolled in the trial on February, 22, 1995 and withdrawn on March 24 after suffering from chest pains. This patient had been randomized to the imipramine arm of study 329.
So the question remains: how did patient #70 go from being a teenage girl who overdosed on Tylenol to a 12-year-old boy with chest pains?
How indeed?
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
The Paxil Papers [Source - Christopher Lane]
This Paxil Fact File, containing confidential information, was drafted and distributed by SmithKline Beecham in 1998--for internal use only.
Foreword by Paul N. Jenner, Director and Vice President of Neuroscience and Strategic Product Development
Section 1: Towards the Second Billion -- All SSRIs Are Not the Same
Section 2: New Indications: Social Anxiety Disorder / Social Phobia
Section 3: Issues Management: Managing the Discontinuation Issue.
Related Papers
"Duration of Treatment and Depression: Relapse and Recurrence Rates" (February 2001; GlaxoSmithKline Confidential--Internal Use Only).
"Paxil CR" Product Monograph (GlaxoSmithKline; November 1, 2005).
Paxil Litigation Documents (Filed Under Seal; November 11, 2007).
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING